12.11

1.76% 0.21

After Hours: 12.09 -0.02 -0.17%

Mineralys Therapeutics Inc (MLYS)

Overview News Price History Option Chain Financials Discussions Forecast

Mineralys Therapeutics Inc stock is traded at $12.11, with a volume of 72,682. It is up +1.76% in the last 24 hours and down -2.42% over the past month. Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.

Previous Close:

$11.90

Open:

$11.81

24h Volume:

72,682

Relative Volume:

0.35

Market Cap:

$597.22M

Revenue:

Net Income/Loss:

$-119.67M

P/E Ratio:

-8.5856

EPS:

-1.4105

Net Cash Flow:

$-97.30M

1W Performance:

+5.76%

1M Performance:

-2.42%

6M Performance:

-6.20%

1Y Performance:

+27.34%

1-Day Range:

$11.77

$12.17

1-Week Range:

$11.26

$12.27

52-Week Range:

$5.85

$16.91

Mineralys Therapeutics Inc Stock (MLYS) Company Profile

Name

Mineralys Therapeutics Inc

Sector

Healthcare (1190)

Industry

Biotechnology (681)

Phone

(888) 378-6240

Address

150 N. RADNOR CHESTER ROAD, RADNOR

Employee

Twitter

Next Earnings Date

2024-08-13

Latest SEC Filings

MLYS's Discussions on Twitter

Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-07-23	Initiated	BofA Securities	Buy
Mar-07-23	Initiated	Credit Suisse	Outperform
Mar-07-23	Initiated	Evercore ISI	Outperform
Mar-07-23	Initiated	Guggenheim	Buy
Mar-07-23	Initiated	Stifel	Buy
Mar-07-23	Initiated	Wells Fargo	Overweight

View All

Mineralys Therapeutics Inc Stock (MLYS) Latest News

05:34 AM

Driehaus Capital Management LLC Increases Holdings in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - MarketBeat

05:34 AM

02:30 AM

Mineralys Therapeutics Hits Enrollment Milestone in Hypertension Drug Trial - MSN

02:30 AM

Sep 29, 2024

Mineralys Therapeutics to Speak at Wells Fargo Healthcare Conference - MSN

Sep 29, 2024

Sep 28, 2024

Blue Owl Capital Holdings LP Has $5.27 Million Stock Position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - MarketBeat

Sep 28, 2024

Sep 27, 2024

MLYSMineralys Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Sep 27, 2024

Sep 26, 2024

Mineralys Therapeutics Hits Enrollment Milestone in Hypertension Drug Trial - MyChesCo

Sep 26, 2024

Sep 25, 2024

Mineralys Therapeutics Hits Enrollment Milestone in Hypertension Trial - TipRanks

Sep 25, 2024

Mineralys Therapeutics completes target enrollment for Advance-HTN Trial - TipRanks

Sep 25, 2024

Mineralys Therapeutics, Inc. Completes Target Enrollment in Pivotal Advance-Htn Trial of Lorundrostat for the Treatment of Hypertension - Marketscreener.com

Sep 25, 2024

Mineralys Therapeutics Completes Target Enrollment in - GlobeNewswire

Sep 25, 2024

Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-HTN Trial of Lorundrostat for the Treatment of Hypertension - StockTitan

Sep 25, 2024

Sep 24, 2024

Goldman starts Mineralys at buy, cites upcoming drug data - MSN

Sep 24, 2024

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Mineralys Therapeutics, Inc. (MLYS) and Encourages Shareholders to Learn More About the Investigation - AccessWire

Sep 24, 2024

American Century Companies Inc. Buys 23,170 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - Defense World

Sep 24, 2024

Sep 23, 2024

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Shares Sold by Adams Street Partners LLC - Defense World

Sep 23, 2024

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Shares Sold by Adams Street Partners LLC - MarketBeat

Sep 23, 2024